Safety of omalizumab in the treatment of moderate-to-severe bronchial asthma

Abstract

This review aimed to analyze national and international literature on the safety of omalizumab in the treatment of moderate-to-severe bronchial asthma. Omalizumab is one of the longest-standing monoclonal antibodies and the first available treatment option for severe allergic asthma in patients aged ≥6 years. Several randomized controlled studies have established its efficiency and safety, leading to its final registration more than 15 years ago. In most cases, long-term treatment with omalizumab is safe without increasing the risk of adverse reactions. However, over the years, a growing trend has been observed in several registrations of adverse events associated with the use of omalizumab. A review of the literature revealed a lack of long-term clinical monitoring data (over 2 years) in both patients aged >18 years and children. Long-term adverse reactions during omalizumab therapy are insufficiently examined and require more detailed analysis, despite reports of an association between omalizumab and some adverse events. Moreover, extremely few cases of adverse reactions to omalizumab were reported in the Russian Federation. Thus, further investigations of the safety profile of omalizumab and monitoring of its delayed adverse reactions are required.

Keywords

review / bronchial asthma / omalizumab / recurrent wheezing / adverse reactions / safety

References

[1] Ginasthma.org [Internet]. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [cited 2022 May 10]. Available from: www.ginasthma.org

[2] Ginasthma.org [Internet]. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [дата обращения: 10.05.2022]. Доступ по ссылке: www.ginasthma.org

[3] Klinicheskie rekomendatsii Ministerstva Zdravookhraneniya Rossiiskoi Federatsii: Bronkhial'naya astma. Available from: https://raaci.ru/dat/pdf/allergic_rhinitis.pdf. Accessed: 10.05.2022.

[4] Клинические рекомендации Министерства здравоохранения Российской Федерации: Бронхиальная астма. Режим доступа: https://raaci.ru/dat/pdf/allergic_rhinitis.pdf. Дата обращения: 10.05.2022.

[5] Namazova-Baranova LS, Vishneva EA, Dobrynina EA, et. al. Primary results of long-term dynamic monitoring of children with bronchial asthma of uncontrolled severe persistent course. Pediatric pharmacology. 2016; 13(6):554–559. doi: 10/15690/pf.v13i6.1668. (In Russ).

[6] Намазова-Баранова Л.С., Вишнева Е.А., Добрынина Е.А., и др. Первые результаты длительного динамического мониторинга детей с бронхиальной астмой тяжелого персистирующего неконтролируемого течения // Педиатрическая фармакология. 2016. Т. 13, № 6. С. 554–559. doi: 10/15690/pf.v13i6.1668

[7] Cdc.gov/asthma/most_recent_data.htm [Internet]Centers for Disease Control and Prevention, Asthma Data. [cited 2022 May 10]. Available from: http://www.cdc.gov/asthma/most_recent_data.htm

[8] Cdc.gov/asthma/most_recent_data.htm [Internet]. Centers for Disease Control and Prevention, Asthma Data. [дата обращения: 10.05.2022]. Доступ по ссылке: http://www.cdc.gov/asthma/most_recent_data.htm

[9] Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organization Journal. 2014;7(1):12. doi: 10.1186/1939-4551-7-12

[10] Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action // World Allergy Organ J. 2014. Vol. 7, N 1. P. 12. doi: 10.1186/1939-4551-7-12

[11] Tsai M-K, Lin Y-C, Huang M-Y, et al. The effects of asthma medications on reactive oxygen species production in human monocytes. J Asthma. 2017;55(4):345–353. doi: 10.1080/02770903.2017.1339798

[12] Tsai M.-K., Lin Y.-C., Huang M.-Y., et al. The effects of asthma medications on reactive oxygen species production in human monocytes // J Asthma. 2017. Vol. 55, N 4. P. 345–353. doi: 10.1080/02770903.2017.1339798

[13] Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1). doi: 10.1183/13993003.00588-2019

[14] Holguin F., Cardet J.C., Chung K.F., et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline // Eur Respir J. 2020. Vol. 55, N 1. doi: 10.1183/13993003.00588-2019

[15] Mitskevich SE, Fedorov IA, Chuprynina AI, Rybakova OG. Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children. Doctor.Ru. 2020;19(3):53–56. doi: 10.31550/1727-2378-2020-19-3-53-56

[16] Мицкевич С.Э., Федоров И.А., Чупрынина А.И., Рыбакова О.Г. Опыт применения омализумаба в лечении тяжелой неконтролируемой бронхиальной астмы у детей // Доктор.Ру. 2020; Т. 19, № 3. С. 53–56. doi: 10.31550/1727-2378-2020-19-3-53-56

[17] Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2013;43(2):343-373. doi: 10.1183/09031936.00202013

[18] Chung K.F., Wenzel S.E., Brozek J.L., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma // Eur Respir J. 2013. Vol. 43, N 2. P. 343–373. doi: 10.1183/09031936.00202013

[19] Abraham I, Alhossan A, Lee CS, et al. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610. doi: 10.1111/all.12815

[20] Abraham I., Alhossan A., Lee C.S., et al. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review // Allergy. 2016. Vol. 71, N 5. P. 593–610. doi: 10.1111/all.12815

[21] Federal'nye klinicheskie rekomendatsii po okazaniyu meditsinskoi pomoshchi detyam s bronkhial'noi astmoi. Available from: https://www.vodkb.ru/wp-content/uploads/2017/03/brast.pdf. Accessed: May 10, 2022. (In Russ).

[22] Федеральные клинические рекомендации по оказанию медицинской помощи детям с бронхиальной астмой. Режим доступа: https://www.vodkb.ru/wp-content/uploads/2017/03/brast.pdf. Дата обращения: 10.05.2022.

[23] Il'ina NI, Namazova-Baranova LS, Emel’yanov AV et al. Algoritm naznacheniya immunobiologicheskikh preparatov pri tyazheloi atopicheskoi bronkhial’noi astme v Rossii (soglasitel'nyi dokument). Rossiiskii allergologicheskii zhurnal. 2014. (4):26–27. (In Russ).

[24] Ильина Н.И., Намазова-Баранова Л.С., Емельянов А.В. и др. Алгоритм назначения иммунобиологических препаратов при тяжелой атопической бронхиальной астме в России (согласительный документ) // Российский аллергологический журнал. 2014. № 4. С. 26–27.

[25] Darveaux J, Busse WW. Biologics in Asthma–The Next Step Toward Personalized Treatment. J Allergy Clin Immunol Pract. 2015;3(2):152–160. doi: 10.1016/j.jaip.2014.09.014

[26] Darveaux J., Busse W.W. Biologics in Asthma—The Next Step Toward Personalized Treatment // J Allergy Clin Immunol Pract. 2015. Vol. 3, N 2. P. 152–160. doi: 10.1016/j.jaip.2014.09.014

[27] Licari A, Marseglia A, Caimmi S, et al. Omalizumab in Children. Paediatr Drugs. 2014;16(6):491–502. doi: 10.1007/s40272-014-0107-z

[28] Licari A., Marseglia A., Caimmi S., et al. Omalizumab in Children // Paediatr Drugs. 2014. Vol. 16, N 6. P. 491–502. doi: 10.1007/s40272-014-0107-z

[29] Grls.rosminzdrav.ru/default.aspx. Instruktsiya po primeneniyu preparata omalizumab. Available from: https://grls.rosminzdrav.ru/default.aspx. Accessed: May 10, 2022. (In Russ).

[30] Grls.rosminzdrav.ru/default.aspx. Инструкция по применению препарата омализумаб. Режим доступа: https://grls.rosminzdrav.ru/default.aspx. Дата обращения: 10.05.2022.

[31] Kurbacheva OM, Galitskaya MA. The place of Omalizumab in the treatment of allergic diseases. Medical Council. 2019(15):38–49. doi: 10.21518/2079-701x-2019-15-38-49

[32] Курбачева О.М., Галицкая М.А. Место омализумаба в терапии аллергических заболеваний // Медицинский совет. 2019. № 15. С. 38–49. doi: 10.21518/2079-701X-2019-15-38-49

[33] Licari A, Manti S, Castagnoli R, et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Paediatr Drugs. 2019;21(4):215–237. doi: 10.1007/s40272-019-00345-7

[34] Licari A., Manti S., Castagnoli R., et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives // Paediatr Drugs. 2019. Vol. 21, N 4. P. 215–237. doi: 10.1007/s40272-019-00345-7

[35] Odajima H, Ebisawa M, Nagakura T, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106–115. doi: 10.1016/j.alit.2016.06.004

[36] Odajima H., Ebisawa M., Nagakura T., et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma // Allergol Int. 2017. Vol. 66, N 1. P. 106–115. doi: 10.1016/j.alit.2016.06.004

[37] Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med. 2010;103(3):98–106. doi: 10.1258/jrsm.2009.090348

[38] Simpson C.R., Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients // J R Soc Med. 2010. Vol. 103, N 3. P. 98–106. doi: 10.1258/jrsm.2009.090348

[39] Noop A, Johansson SG, Adedoyin J. et al. After 6 years with Xolair; 3-year withdrawal follow-up. Allergy. 2010;(1):156–160. doi: doi.org/10.1111/j.1398-9995.2009.02144.x

[40] Noop A., Johansson S.G., Adedoyin J. et al. After 6 years with Xolair; 3-year withdrawal follow-up // Allergy. 2010. № 1. C. 156–160. doi: doi.org/10.1111/j.1398-9995.2009.02144.x

[41] Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016;6(8). doi: 10.1136/bmjopen-2016-011857

[42] Niven R.M., Saralaya D., Chaudhuri R., et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study) // BMJ Open. 2016. Vol. 6, N 8. doi: 10.1136/bmjopen-2016-011857

[43] Strel’tsov EA, Demidov VS, Tsoy LV, et al. Safety and efficiency of using Omaulizumab in bronchial asthma. Medical Herald of the South of Russia. 2019;10(2):6–12. doi: 10.21886/2219-8075-2019-10-2-6-12

[44] Стрельцов Е.А., Демидов В.А., Цой Л.В., и др. Безопасность и эффективность применения омализумаба при бронхиальной астме // Медицинский вестник Юга России 2019. Т. 10, № 2. Р. 6–12. doi: 10.21886/2219-8075-2019-10-2-6-12

[45] Vishneva EA, Namazova-Baranova LS, Dobrynina EA, et al. The Long-Term Omalizumab Therapy in Children with Severe Persistent Uncontrolled Asthma: Evaluation of the Outcomes According to the Data of the Hospital Patient Registry. Pediatric pharmacology. 2018;15(2):149-158. doi: 10.15690/pf.v15i2.1877

[46] Вишнева Е.А., Намазова-Баранова Л.С., Добрынина Е.А., и др. Длительный курс терапии омализумабом у детей с тяжелой персистирующей неконтролируемой бронхиальной астмой: оценка результатов по данным локального регистра // Педиатрическая фармакология. 2018. Т. 15, № 2. С. 149–158. doi: 10.15690/pf.v15i2.1877

[47] Melikhov OG. Klinicheskie issledovaniya. 3-e izdanie dopolnennoe. Moscow: Atmosfera; 2013.

[48] Мелихов О.Г. Клинические исследования. 3-е издание дополненное. Москва: Атмосфера, 2013.

[49] Sousa J, Taborda-Barata L, Monteiro C. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system. Expert Opin Drug Safe. 2019;19(1):99–106. doi: 10.1080/14740338.2020.1686481

[50] Sousa J., Taborda-Barata L., Monteiro C. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system // Expert Opin Drug Safe. 2019. Vol. 19, N 1. P. 99–106. doi: 10.1080/14740338.2020.1686481

[51] Di Bona D, Fiorino I, Taurino M, et al. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med. 2017;130:55–60. doi: 10.1016/j.rmed.2017.07.013

[52] Di Bona D., Fiorino I., Taurino M., et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study // Respir Med. 2017. Vol. 130, N. P. 55–60. doi: 10.1016/j.rmed.2017.07.013

[53] Li L, Wang Z, Cui L, et al. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clin Transl Allergy. 2021;11(4). doi: 10.1002/clt2.12038

[54] Li L., Wang Z., Cui L., et al. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab // Clin Transl Allergy. 2021. Vol. 11, N 4. doi: 10.1002/clt2.12038

[55] Bian S, Zhang P, Li L, et al. Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System. Front Pharmacol. 2021;12. doi: 10.3389/fphar.2021.767999

[56] Bian S., Zhang P., Li L., et al. Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System // Front Pharmacol. 2021. Vol. 12, N P. doi: 10.3389/fphar.2021.767999

[57] Lieberman PL, Jones I, Rajwanshi R, et al. Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics. J Allergy Clin Immunol. 2017;140(6):1734–1736.e1734. doi: 10.1016/j.jaci.2017.07.013

[58] Lieberman P.L., Jones I., Rajwanshi R., et al. Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics // J Allergy Clin Immunol. 2017. Vol. 140, N 6. P. 1734–1736.e1734. doi: 10.1016/j.jaci.2017.07.013

[59] Harrison RG, MacRae M, Karsh J, et al. Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience. Ann Allergy, Asthma Immunol. 2015;115(1):77–78. doi: 10.1016/j.anai.2015.04.014

[60] Harrison R.G., MacRae M., Karsh J., et al. Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience // Ann Allergy Asthma Immunol. 2015. Vol. 115, N 1. P. 77–78. doi: 10.1016/j.anai.2015.04.014

[61] Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study. J Allergy Clin Immunol. 2016;138(3):913–915.e912. doi: 10.1016/j.jaci.2016.03.030

[62] Lieberman P.L., Umetsu D.T., Carrigan G.J., Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study // J Allergy Clin Immunol. 2016. Vol. 138, N 3. P. 913–915.e912. doi: 10.1016/j.jaci.2016.03.030

[63] Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120(6):1378–1381. doi: 10.1016/j.jaci.2007.09.022

[64] Limb S.L., Starke P.R., Lee C.E., Chowdhury B.A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma // J Allergy Clin Immunol. 2007. Vol. 120, N 6. P. 1378–1381. doi: 10.1016/j.jaci.2007.09.022

[65] Nazir S, Tachamo N, Fareedy SB, et al. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy, Asthma Immunol. 2017;118(3):372–374.e371. doi: 10.1016/j.anai.2016.12.003.

[66] Nazir S., Tachamo N., Fareedy S.B., et al. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) // Ann Allergy Asthma Immunol. 2017. Vol. 118, N 3. P. 372–374.e371. doi: 10.1016/j.anai.2016.12.003

[67] Winchester DE, Jacob A, Murphy T. Omalizumab for Asthma. N Engl J Med. 2006;355(12):1281-1282. doi: 10.1056/NEJMc061914

[68] Winchester D.E., Jacob A., Murphy T. Omalizumab for Asthma // N Engl J Med. 2006. Vol. 355, N 12. P. 1281–1282. doi: 10.1056/NEJMc061914

[69] Bargagli E, Rottoli P. Omalizumab Treatment Associated with Churg-Strauss Vasculitis. Int Arch Allergy Immunol. 2008;145(3):268–268. doi: 10.1159/000109296

[70] Bargagli E., Rottoli P. Omalizumab Treatment Associated with Churg-Strauss Vasculitis // Int Arch Allergy Immunol. 2008. Vol. 145, N 3. P. 268–268. doi: 10.1159/000109296

[71] Yamaki Y, Hayashi D, Honda K, et al. A case of omalizumab-associated eosinophilic granulomatosis with polyangiitis. Pediatr Int. 2021;63(9):1119–1121. doi: 10.1111/ped.14540

[72] Yamaki Y., Hayashi D., Honda K., et al. A case of omalizumab-associated eosinophilic granulomatosis with polyangiitis // Pediatr Int. 2021. Vol. 63, N 9. P. 1119–1121. doi: 10.1111/ped.14540

[73] Elhadari S, Hammad M. Transient eosinophilic granulomatosis with polyangiitis-like vasculitis during omalizumab therapy: a case report. Open Access Rheumatol. 2020;12:127–131. doi: 10.2147/oarrr.s259746

[74] Elhadari S., Hammad M. Transient eosinophilic granulomatosis with polyangiitis-like vasculitis during omalizumab therapy: a case report // Open Access Rheumatol. 2020. Vol. 12, N. P. 127–131. doi: 10.2147/oarrr.s259746

[75] Carson LN, Pradhan A, Subramanian D. Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence? BMJ Case Rep. 2021;14(7). doi: 10.1136/bcr-2020-240078

[76] Carson L.N., Pradhan A., Subramanian D. Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence? // BMJ Case Rep. 2021. Vol. 14, N 7. P. doi: 10.1136/bcr-2020-240078

[77] Bekcibasi M, Barutcu S, Celen MK, et al. Churg-Strauss syndrome occurring during omalizumab treatment. Eur J Rheumatol. 2015;2(3):129–130. doi: 10.5152/eurjrheum.2015.0086

[78] Bekcibasi M., Barutcu S., Celen M.K., et al. Churg-Strauss syndrome occurring during omalizumab treatment // Eur J Rheumatol. 2015. Vol. 2, N 3. P. 129–130. doi: 10.5152/eurjrheum.2015.0086

[79] Lau EMT, Cooper W, Bye PT, Yan K. Difficult asthma and Churg-Strauss-like syndrome: A cautionary tale. Respirology. 2011;16(1):180–181. doi: 10.1111/j.1440-1843.2010.01884.x

[80] Lau E.M.T., Cooper W., Bye P.T., Yan K. Difficult asthma and Churg-Strauss-like syndrome: A cautionary tale // Respirology. 2011. Vol. 16, N 1. P. 180–181. doi: 10.1111/j.1440-1843.2010.01884.x

[81] Szwarc D, Veillon F, Moser T, et al. Syndrome de Churg et Strauss sous omalizumab : une manifestation viscérale exceptionnelle. J Radiol. 2009;90(11):1737–1739. doi: 10.1016/s0221-0363(09)73273-1

[82] Szwarc D., Veillon F., Moser T., et al. Syndrome de Churg et Strauss sous omalizumab: une manifestation viscérale exceptionnelle // J Radiol. 2009. Vol. 90, N 11. P. 1737–1739. doi: 10.1016/s0221-0363(09)73273-1

[83] Cazzola M, Mura M, Segreti A, et al. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome? Allergy. 2009;64(9):1389–1390. doi: 10.1111/j.1398-9995.2009.02061.x

[84] Cazzola M., Mura M., Segreti A., et al. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy:forme-frusteof Churg-Strauss syndrome? // Allergy. 2009. Vol. 64, N 9. P. 1389–1390. doi: 10.1111/j.1398-9995.2009.02061.x

[85] Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss Syndrome in Patients Treated With Omalizumab. Chest. 2009;136(2):507–518. doi: 10.1378/chest.08-2990

[86] Wechsler M.E., Wong D.A., Miller M.K., Lawrence-Miyasaki L. Churg-Strauss Syndrome in Patients Treated With Omalizumab // Chest. 2009. Vol. 136, N 2. P. 507–518. doi: 10.1378/chest.08-2990

[87] Puéchal X, Rivereau P, Vinchon F. Churg–Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008;19(5):364–366. doi: 10.1016/j.ejim.2007.09.001

[88] Puéchal X., Rivereau P., Vinchon F. Churg–Strauss syndrome associated with omalizumab // Eur J Intern Med. 2008. Vol. 19, N 5. P. 364–366. doi: 10.1016/j.ejim.2007.09.001

[89] Bargagli E, Madioni C, Olivieri C, et al. Churg-Strauss Vasculitis in a Patient Treated with Omalizumab. J Asthma. 2009;45(2):115–116. doi: 10.1080/02770900701767704

[90] Bargagli E., Madioni C., Olivieri C., et al. Churg-Strauss Vasculitis in a Patient Treated with Omalizumab // J Asthma. 2009. Vol. 45, N 2. P. 115–116. doi: 10.1080/02770900701767704

[91] Ruppert A-M, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008;121(1):253–254. doi: 10.1016/j.jaci.2007.10.040

[92] Ruppert A.-M., Averous G., Stanciu D., et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment // J Allergy Clin Immunol. 2008. Vol. 121, N 1. P. 253–254. doi: 10.1016/j.jaci.2007.10.040

[93] Borekci S, Aydin O, Hatemi G, Gemicioglu B. Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report. Int J Immunopathol Pharmacol. 2015;28(1):134–137. doi: 10.1177/0394632015572567

[94] Borekci S., Aydin O., Hatemi G., Gemicioglu B. Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report // Int J Immunopathol Pharmacol. 2015. Vol. 28, N 1. P. 134–137. doi: 10.1177/0394632015572567

[95] Spina MF, Miadonna A. Role of omalizumab and steroids in Churg-Strauss syndrome. J Allergy Clin Immunol. 2009;124(3):600–601. doi: 10.1016/j.jaci.2009.05.023.

[96] Spina M.F., Miadonna A. Role of omalizumab and steroids in Churg-Strauss syndrome // JJ Allergy Clin Immunol. 2009. Vol. 124, N 3. P. 600–601. doi: 10.1016/j.jaci.2009.05.023

[97] Puéchal X, Rivereau P, Vinchon F. Churg–Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008;19(5):364–366. doi: 10.1016/j.ejim.2007.09.001

[98] Puéchal X., Rivereau P., Vinchon F. Churg–Strauss syndrome associated with omalizumab // Eur J Intern Med. 2008. Vol. 19, N 5. P. 364–366. doi: 10.1016/j.ejim.2007.09.001

[99] Solèr M. Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions. Respiration. 2014;88(2):158–161. doi: 10.1159/000360771

[100] Solèr M. Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions // Respiration. 2014. Vol. 88, N 2. P. 158–161. doi: 10.1159/000360771

[101] Canzian A, Venhoff N, Urban ML, et al. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. Arthritis Rheumatol. 2021;73(3):498–503. doi: 10.1002/art.41534

[102] Canzian A., Venhoff N., Urban M.L., et al. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study // Arthritis Rheumatol. 2021. Vol. 73, N 3. P. 498–503. doi: 10.1002/art.41534

[103] Basta F, Mazzuca C, Nucera E, et al. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature reviews. Clin Exp Rheumatol. 2020;38(124):214-220

[104] Basta F., Mazzuca C., Nucera E., Schiavino D. et al. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature reviews // Clin Exp Rheumatol. 2020. Vol. 38, N 124. P. 214–220.

[105] Mota D, Rama TA, Severo M, Moreira A. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database. Allergy. 2021;76(10):3209–3211. doi: 10.1111/all.15008

[106] Mota D., Rama T.A., Severo M., Moreira A. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database // Allergy. 2021. Vol. 76, N 10. P. 3209–3211. doi: 10.1111/all.15008

[107] Iribarren C, Rothman KJ, Bradley MS, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017;139(5):1678–1680. doi: 10.1016/j.jaci.2016.12.953

[108] Iribarren C., Rothman K.J., Bradley M.S., et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials // J Allergy Clin Immunol. 2017. Vol. 139, N 5. P. 1678–1680. doi: 10.1016/j.jaci.2016.12.953

RIGHTS & PERMISSIONS

Shnaider K.O., Maksimov M.L., Romanov B.K